SRR33346962
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- HEDGEHOG_SIGNALING+0.400
- MYOGENESIS+0.300
- KRAS_SIGNALING_DN+0.290
- UV_RESPONSE_DN+0.180
- APICAL_JUNCTION+0.130
- COAGULATION+0.100
- APICAL_SURFACE+0.090
- KRAS_SIGNALING_UP+0.090
Top 10 suppressed
- MYC_TARGETS_V1-0.650
- E2F_TARGETS-0.600
- MYC_TARGETS_V2-0.570
- OXIDATIVE_PHOSPHORYLATION-0.570
- G2M_CHECKPOINT-0.520
- MTORC1_SIGNALING-0.520
- DNA_REPAIR-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.510
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.480
- CHOLESTEROL_HOMEOSTASIS-0.470
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303745 | — | — | 0.967 |
| 2 | d7bbb44a-3fe0-4455-99d0-90be213f2a31 | — | — | 0.934 |
| 3 | MNG771 | — | — | 0.927 |
| 4 | BS_CZ82ANWP | DNET | — | 0.926 |
| 5 | R415 | — | — | 0.923 |
| 6 | SRR658977 | GTEX | — | 0.922 |
| 7 | SRR1319158 | GTEX | — | 0.918 |
| 8 | SRR12202400 | — | — | 0.914 |
| 9 | d2995480-5ae0-42e1-9a21-25e1435201ee | — | — | 0.912 |
| 10 | SRR1475257 | GTEX | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.470 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.130 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.080 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |